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Abstract
Objectives—To determine the optimal time for a second HIV-1 nucleic acid amplification assay
to detect late postnatal transmission of HIV-1 (first negative test at 4–8 weeks of age) in resource
limited settings.
Design—A longitudinal analysis of data from HPTN 024
Methods—Children born to HIV-1 infected mothers enrolled in the HIV Prevention Trial Network
trial 024 (HPTN 024) were tested for HIV-1 infection at six intervals within the first year of life.
Mothers and infants received nevirapine prophylaxis. We estimated the probability of being alive
and having a positive test in each interval after 4–8 weeks and at 30 days post-weaning, conditional
on having acquired HIV during the late postnatal period. The interval with the highest probability
was taken to be the optimal visit interval.
*Corresponding Author: Susan A. Fiscus, Ph.D., Department of Microbiology and Immunology, University of North Carolina at Chapel
Hill, Chapel Hill, NC 27599-7290.
Author contributions
Authors: Elizabeth Brown developed the model and performed all of the statistical analyses and, in collaboration with Susan Fiscus,
designed the study and wrote the first drafts and revisions to the manuscript. Taha Taha and Robert Goldenberg were Protocol Chairs of
the original HPTN 024 study and edited this manuscript. Jennifer Read and Usha Sharma represent the agencies that funded HPTN 024
(NICHD and NIAID),provided critical reviews of the manuscript during the drafting stages, and approved each submitted version.
Benjamin Chi and Robert Goldenberg (Lusaka), Irving Hoffman (Lilongwe), Taha Taha (Blantyre) and Cheryl Pikora (Dar es Salaam)




AIDS. Author manuscript; available in PMC 2009 November 12.
Published in final edited form as:













Results—A total of 1609 infants from HPTN 024 had at least one HIV-1 diagnostic test and were
included in the analysis. We found that testing at one month after weaning or 12 months of age
(whichever comes first), identified 81% of those infected during the late postnatal period (after 4–8
weeks) through breastfeeding. In total, 93% (95% CI: 89,98) of all infected infants would be detected
if tests were performed at these two time points.
Conclusions—In resource-limited settings, HIV-1 PCR testing at 4–8 weeks followed by a second
test at one month after weaning or at one year of age (whichever comes first), led to the identification
of the vast majority of HIV-1 infected infants.
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Introduction
HIV-1 serology cannot be used to diagnose perinatal HIV-1 infection among children under
18 months born to HIV-1 infected women due to the presence of maternal, HIV-1 specific
antibodies which cross the placenta during gestation. Infants in resource rich settings are tested
repeatedly to establish their HIV infection status during the first few weeks and months of life
using polymerase chain reaction (PCR)-based assays that detect either proviral HIV DNA or
viral RNA in blood. However, in resource-limited settings. repeated PCR testing is usually not
possible due to budgetary and infrastructure constraints. Routine PCR testing at 4–8 weeks of
age, which detects 95%–99% of in utero and peripartum infections (1–3), may be feasible
because it coincides with scheduled visits in many national health plans.
However, if an infant is breastfed, the risk of transmission continues. In resource limited
settings, clinicians commonly wait until 15–18 months of age, when complete cessation of
breastfeeding has frequently occurred, to conduct HIV-1 diagnostic testing using a less
expensive and more accessible antibody test. Relying on serological testing at 15–18 months
delays life saving initiation of antiretroviral therapy (ART) (4) and the infant may die or become
lost to clinical care prior to 15–18 months of age. Early infection has been associated with
increased mortality (5–13). Therefore, determination of a single additional HIV testing
timepoint for children after 4–8 weeks of age would have great practical value for global HIV/
AIDS programs and could provide a cost-effective method for infant HIV-1 diagnosis.
Using data from the HIV Prevention Trials Network (HPTN) 024 trial, we estimated the
proportion of HIV-1 infected infants who were still alive (and therefore who could have ART
initiated) if they were tested at one of a set of time points. We sought to establish an optimal
visit time for a second HIV-1 virologic test after 4–8 weeks of age to detect late postnatal
transmission (transmission between 4–8 weeks and one year) in breastfed infants. Our
definition of the optimal time for HIV-1 testing after 4–8 weeks was when the majority of
infants who were infected in the late postnatal period would be captured. If there were no deaths
due to HIV-1 infection, this visit could be when the child had completely weaned. However,
because HIV-1 related deaths often occur prior to this (4–13), the optimal visit time we propose
represents a window period late enough that most HIV-1 infections have occurred, but early
enough that few of these HIV-1 infected infants have died.
Materials and Methods
Patient Population
We analyzed data from subjects enrolled in HPTN 024. This was a multi-site, double-blinded,
placebo-controlled randomized trial of antibiotics to prevent chorioamnionitis-associated
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mother-to-child transmission (MTCT) of HIV-1 and preterm birth (14). All mothers and infants
received single dose nevirapine prophylaxis following the HIVNET 012 protocol (15). Infants
underwent HIV-1 diagnostic testing using HIV-1 RNA assays at birth, at 4–8 weeks, and at
three, six, nine, and 12 months of age. Of the four sites in HPTN 024, one counseled women
to wean at six months (Dar es Salaam, Tanzania), and these data were not used in the analysis.
Data from the three other sites in Lilongwe and Blantyre, Malawi, and Lusaka, Zambia, were
analyzed. Breast feeding duration at these three sites was similar with 93–97% still
breastfeeding at six months, 86–93% at nine months and 77–87% at 12 months with details
previously published (16).
Statistical Methods
In the model we define s to be the imprecisely measured time an infant would first test positive
for HIV-1 and u to be the time of death. Because s is only known within an interval (e.g. some
time between the last negative and the first positive PCR result), we used a multiple imputation
procedure specifically designed for MTCT of HIV-1 (17). Briefly, the imputation procedure
was implemented 10 times resulting in 10 data sets with imputed values for s when the event
time was interval or right censored. The analysis was run on each of the data sets. Rubin’s rules
(18) for combining results from imputed data analyses were used to obtain the final results.
We estimated the optimal visit time as follows: The variables t1,…, tJ denote the times of the
J visits under consideration for HIV-1 testing beyond 4–8 weeks. At the jth, j = 1,…, J, visit,
occurring at tj, the number of infants who are alive and would test positive is denoted by nj
(the total number of infants with s≤tj & u>tj) which follows a binomial distribution with mean
pj × m where m is the total number of infants who acquired HIV-1 infection through late
postnatal transmission and pj probability of being alive and testing positive at tj conditional on
acquiring HIV-1 infection through late postnatal transmission. An unbiased estimate of pj is
given by nj/m. We defined the optimal visit time as the visit for which pj is greatest.
Figure 1 illustrates an example of this procedure using hypothetical data with the same visit
structure as HPTN 024. In this example, subjects 1 and 6 are not included because their HIV-1
infection was detected at the 4–8 week visit. There are J=4 visit times. Of the m=7 infants who
test positive for HIV-1 infection within the first year, four (57%) are positive and alive at t1=
three months (subjects 2, 3, 4, and 9). Therefore, if testing occurred at that point, only 57% of
the infections would be detected. At t2 = 6 months, subjects 2, 3, 5, 8, and 9 (71%) would be
infected and detected. However, at t3=9 and t4= 12 months, just four of the seven (p3=p4=57%)
infections would be detected. Because the largest pj is p2, this hypothetical example indicates
that six months would be the optimal additional testing point. To determine the proportion of
infants who would be captured if testing was only performed at six weeks and three, six, nine
or 12 months, we used a similar procedure as above with nj equaling the number of infants
who would first test positive at six weeks or the jth month and m equaling the total number of
infants infected before their first birthday (including cases of in utero and intrapartum
infection).
Because duration of breastfeeding could influence the results, we also performed an alternate
analysis that defined infant-specific testing times at one month after weaning or at one year of
age, whichever comes first. The procedure for calculating the proportion detected under this
algorithm is identical to the one described above except for adding a tj that varies over infants.
Results
Of 1671 infants born to HIV-1 infected women enrolled in HPTN 024 at the three African
sites, 1609 (96.3%) had at least one HIV-1 diagnostic test. Figure 2 summarizes the HIV-1
infection status of these infants at 12 months of age, if known, or, if unknown, the timing of
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their last negative test. At 12 months of age, 336 infants (20.8%) had at least one positive HIV-1
diagnostic test result, 830 (51.5%) had only negative results, and 443 (27.5%) were of uncertain
HIV-1 infection status and therefore had their HIV-1 infection status imputed as part of the
multiple imputation procedure.
Our model determined the optimal time point to test for HIV-1 by estimating the proportion
of infants who first test positive in HPTN 024, after excluding those who had been diagnosed
as infected at birth or 4–8 weeks. At three months only 43% [95% confidence interval (95%
CI): 33, 54] of HIV-1 infections would be detected. This increases to 68% (95% CI: 59, 79) at
six months, 78% (95% CI: 69, 87) at nine months, 77% (95% CI: 68, 86) at 12 months and
81% (95% CI: 71, 91) at the time of weaning plus one month or 12 months, whichever came
first. Although the 9 and 12 month confidence intervals include the highest estimate (81%),
the weaning plus one month/12 month algorithm met the criteria defined a priori for
designating the optimal testing time. When we included HIV-1 PCR results from the six week
window, the cumulative proportion of HIV-1-infected infants captured by our testing algorithm
was 85% (95% CI: 80,90) at three months, 91% (95% CI: 87, 95) at six months, 93% (95%
CI: 90, 96) at nine months, 93% (95% CI: 90, 96) at 12 months, and 93% (95% CI: 89, 98) at
the first of one month after weaning or 12 months.
Discussion
Natural history studies have shown that 10–20% and 35–40% of untreated, HIV-1-infected
children in resource-rich and resource-poor settings, respectively, die by two years of age (5–
13). Several reports have indicated that early HIV-1 infection in infants is associated with early
mortality (11,12). Early identification of HIV-1 infection and initiation of appropriate treatment
can delay disease progression significantly (4). Thus, diagnostic testing of all HIV-exposed
infants should be performed at a younger age (by 4–8 weeks of age), coincident with a routine
infant vaccination visit, if possible. Such testing will identify those infants infected in utero,
peripartum, and by early transmission through breast milk. Overall, in HPTN 024, 78% of all
cases of HIV-1 transmission were detected at six weeks of age (16). The remaining 22% of
infected infants were infected during the late postnatal period. This is similar to other studies
(15,19–25).
Our results indicate that, among breastfeeding, HIV-1-exposed infants, HIV-1 diagnostic
testing using a virologic assay should be performed at 4–8 weeks of age to capture early HIV-1
transmission, and at the first of one month after weaning or 12 months of age to capture late
postnatal transmission. This does not preclude additional HIV-1 testing in symptomatic infants
or testing one month after the complete cessation of breastfeeding, if breastfeeding continues
after 12 months. Incorporation of HIV-1 antibody assays beginning at 12 months of age may
also be of benefit since a negative result could be definitive among non-breastfeeding infants
and may thus reduce the number of virologic assays that need to be performed (26).
Although these results suggest testing at one month post-weaning, this may not in fact be
realistic in many resource-poor settings where caretakers must travel long distances for clinical
care. Many caretakers may instead wish to wait until a scheduled clinic visit instead of making
an extra trip to the clinic. In this case, our results suggest the testing at the 9 or 12 month visit
is also an adequate approach, resulting in roughly the same proportion of infections detected.
These results were obtained using data from HPTN 024 where single dose nevirapine given to
the mother during labor and to the infant shortly after birth was used for prevention of MTCT
of HIV-1 (14,15). If other interventions to prevent MTCT of HIV-1 are used, such as prolonged
prophylactic treatment of the infant with nevirapine, or highly active antiretroviral therapy to
the lactating mother, the optimal timing for diagnostic testing, and the most sensitive virologic
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test used (HIV-1 DNA vs HIV-1 RNA) may be different. As described above, duration of breast
feeding also would make a difference in the optimal timing of a second test. For instance, in
HPTN 024, mothers at one site stopped breast feeding at 6 months. In this case, the optimal
timing for a second test would presumably be a combination of one month after weaning and
between six and nine months. Exclusive breastfeeding was not recommended in HPTN 024
which was conducted before the benefits of exclusive breastfeeding were widely accepted. We
did not capture data on breast feeding practices, such as mixed or exclusive breast feeding
which may have affected transmission rates and potentially change the optimal time for a
second HIV diagnostic test. With these caveats in mind, the model used in this study to estimate
the most efficient and cost-effective timing of a second diagnostic test should prove useful with
regard to other strategies for the prevention of MTCT in resource limited settings.
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